Peginterferon plus adefovir versus either drug alone for hepatitis delta

[Guest guest]

N Engl J Med. 2011 Jan 27;364(4):322-31.

Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H,

Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP;

HIDIT Study Group.Collaborators (22)

Akarca US, Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G,

Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein

K, Hardt H, Porst H, Mederacke I, Rigopoulou I, Şentürk H, Tabak F, v Wagner

EK, Yalçın K.

Hannover Medical School, Hannover, Germany.

Abstract

BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus

(HDV) results in the most severe form of viral hepatitis. There is no currently

approved treatment. We investigated the safety and efficacy of 48 weeks of

treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon

alfa-2a alone, and adefovir dipivoxil alone.

METHODS: We conducted a randomized trial in which 31 patients with HDV infection

received treatment with 180 μg of peginterferon alfa-2a weekly plus 10 mg of

adefovir daily, 29 received 180 μg of peginterferon alfa-2a weekly plus

placebo, and 30 received 10 mg of adefovir alone weekly for 48 weeks. Follow-up

was conducted for an additional 24 weeks. Efficacy end points included clearance

of HDV RNA, normalization of alanine aminotransferase levels, and a decline in

levels of hepatitis B surface antigen (HBsAg).

RESULTS: The primary end point--normalization of alanine aminotransferase levels

and clearance of HDV RNA at week 48--was achieved in two patients in the group

receiving peginterferon alfa-2a plus adefovir and two patients in the group

receiving peginterferon alfa-2a plus placebo but in none of the patients in the

group receiving adefovir alone. At week 48, the test for HDV RNA was negative in

23% of patients in the first group, 24% of patients in the second, and none of

those in the third (P = 0.006 for the comparison of the first and third groups;

P = 0.004 for the comparison of the second and third). The efficacy of

peginterferon alfa-2a was sustained for 24 weeks after treatment, with 28% of

the patients receiving peginterferon alfa-2a plus adefovir or peginterferon

alfa-2a alone having negative results on HDV-RNA tests; none of the patients

receiving adefovir alone had negative results. A decline in HBsAg levels of more

than 1 log(10) IU per milliliter from baseline to week 48 was observed in 10

patients in the first group, 2 in the second, and none in the third (P<0.001 for

the comparison of the first and third groups and P = 0.01 for the comparison of

the first and second).

CONCLUSIONS: Treatment with peginterferon alfa-2a for 48 weeks, with or without

adefovir, resulted in sustained HDV RNA clearance in about one quarter of

patients with HDV infection.

(Current Controlled Trials number, ISRCTN83587695.).

PMID: 21268724 [PubMed - in process]

[Guest guest]

N Engl J Med. 2011 Jan 27;364(4):322-31.

Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H,

Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP;

HIDIT Study Group.Collaborators (22)

Akarca US, Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G,

Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein

K, Hardt H, Porst H, Mederacke I, Rigopoulou I, Şentürk H, Tabak F, v Wagner

EK, Yalçın K.

Hannover Medical School, Hannover, Germany.

Abstract

BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus

(HDV) results in the most severe form of viral hepatitis. There is no currently

approved treatment. We investigated the safety and efficacy of 48 weeks of

treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon

alfa-2a alone, and adefovir dipivoxil alone.

METHODS: We conducted a randomized trial in which 31 patients with HDV infection

received treatment with 180 μg of peginterferon alfa-2a weekly plus 10 mg of

adefovir daily, 29 received 180 μg of peginterferon alfa-2a weekly plus

placebo, and 30 received 10 mg of adefovir alone weekly for 48 weeks. Follow-up

was conducted for an additional 24 weeks. Efficacy end points included clearance

of HDV RNA, normalization of alanine aminotransferase levels, and a decline in

levels of hepatitis B surface antigen (HBsAg).

RESULTS: The primary end point--normalization of alanine aminotransferase levels

and clearance of HDV RNA at week 48--was achieved in two patients in the group

receiving peginterferon alfa-2a plus adefovir and two patients in the group

receiving peginterferon alfa-2a plus placebo but in none of the patients in the

group receiving adefovir alone. At week 48, the test for HDV RNA was negative in

23% of patients in the first group, 24% of patients in the second, and none of

those in the third (P = 0.006 for the comparison of the first and third groups;

P = 0.004 for the comparison of the second and third). The efficacy of

peginterferon alfa-2a was sustained for 24 weeks after treatment, with 28% of

the patients receiving peginterferon alfa-2a plus adefovir or peginterferon

alfa-2a alone having negative results on HDV-RNA tests; none of the patients

receiving adefovir alone had negative results. A decline in HBsAg levels of more

than 1 log(10) IU per milliliter from baseline to week 48 was observed in 10

patients in the first group, 2 in the second, and none in the third (P<0.001 for

the comparison of the first and third groups and P = 0.01 for the comparison of

the first and second).

CONCLUSIONS: Treatment with peginterferon alfa-2a for 48 weeks, with or without

adefovir, resulted in sustained HDV RNA clearance in about one quarter of

patients with HDV infection.

(Current Controlled Trials number, ISRCTN83587695.).

PMID: 21268724 [PubMed - in process]

[Guest guest]

N Engl J Med. 2011 Jan 27;364(4):322-31.

Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H,

Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP;

HIDIT Study Group.Collaborators (22)

Akarca US, Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G,

Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein

K, Hardt H, Porst H, Mederacke I, Rigopoulou I, Şentürk H, Tabak F, v Wagner

EK, Yalçın K.

Hannover Medical School, Hannover, Germany.

Abstract

BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus

(HDV) results in the most severe form of viral hepatitis. There is no currently

approved treatment. We investigated the safety and efficacy of 48 weeks of

treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon

alfa-2a alone, and adefovir dipivoxil alone.

METHODS: We conducted a randomized trial in which 31 patients with HDV infection

received treatment with 180 μg of peginterferon alfa-2a weekly plus 10 mg of

adefovir daily, 29 received 180 μg of peginterferon alfa-2a weekly plus

placebo, and 30 received 10 mg of adefovir alone weekly for 48 weeks. Follow-up

was conducted for an additional 24 weeks. Efficacy end points included clearance

of HDV RNA, normalization of alanine aminotransferase levels, and a decline in

levels of hepatitis B surface antigen (HBsAg).

RESULTS: The primary end point--normalization of alanine aminotransferase levels

and clearance of HDV RNA at week 48--was achieved in two patients in the group

receiving peginterferon alfa-2a plus adefovir and two patients in the group

receiving peginterferon alfa-2a plus placebo but in none of the patients in the

group receiving adefovir alone. At week 48, the test for HDV RNA was negative in

23% of patients in the first group, 24% of patients in the second, and none of

those in the third (P = 0.006 for the comparison of the first and third groups;

P = 0.004 for the comparison of the second and third). The efficacy of

peginterferon alfa-2a was sustained for 24 weeks after treatment, with 28% of

the patients receiving peginterferon alfa-2a plus adefovir or peginterferon

alfa-2a alone having negative results on HDV-RNA tests; none of the patients

receiving adefovir alone had negative results. A decline in HBsAg levels of more

than 1 log(10) IU per milliliter from baseline to week 48 was observed in 10

patients in the first group, 2 in the second, and none in the third (P<0.001 for

the comparison of the first and third groups and P = 0.01 for the comparison of

the first and second).

CONCLUSIONS: Treatment with peginterferon alfa-2a for 48 weeks, with or without

adefovir, resulted in sustained HDV RNA clearance in about one quarter of

patients with HDV infection.

(Current Controlled Trials number, ISRCTN83587695.).

PMID: 21268724 [PubMed - in process]

[Guest guest]

N Engl J Med. 2011 Jan 27;364(4):322-31.

Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H,

Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP;

HIDIT Study Group.Collaborators (22)

Akarca US, Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G,

Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein

K, Hardt H, Porst H, Mederacke I, Rigopoulou I, Şentürk H, Tabak F, v Wagner

EK, Yalçın K.

Hannover Medical School, Hannover, Germany.

Abstract

BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus

(HDV) results in the most severe form of viral hepatitis. There is no currently

approved treatment. We investigated the safety and efficacy of 48 weeks of

treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon

alfa-2a alone, and adefovir dipivoxil alone.

METHODS: We conducted a randomized trial in which 31 patients with HDV infection

received treatment with 180 μg of peginterferon alfa-2a weekly plus 10 mg of

adefovir daily, 29 received 180 μg of peginterferon alfa-2a weekly plus

placebo, and 30 received 10 mg of adefovir alone weekly for 48 weeks. Follow-up

was conducted for an additional 24 weeks. Efficacy end points included clearance

of HDV RNA, normalization of alanine aminotransferase levels, and a decline in

levels of hepatitis B surface antigen (HBsAg).

RESULTS: The primary end point--normalization of alanine aminotransferase levels

and clearance of HDV RNA at week 48--was achieved in two patients in the group

receiving peginterferon alfa-2a plus adefovir and two patients in the group

receiving peginterferon alfa-2a plus placebo but in none of the patients in the

group receiving adefovir alone. At week 48, the test for HDV RNA was negative in

23% of patients in the first group, 24% of patients in the second, and none of

those in the third (P = 0.006 for the comparison of the first and third groups;

P = 0.004 for the comparison of the second and third). The efficacy of

peginterferon alfa-2a was sustained for 24 weeks after treatment, with 28% of

the patients receiving peginterferon alfa-2a plus adefovir or peginterferon

alfa-2a alone having negative results on HDV-RNA tests; none of the patients

receiving adefovir alone had negative results. A decline in HBsAg levels of more

than 1 log(10) IU per milliliter from baseline to week 48 was observed in 10

patients in the first group, 2 in the second, and none in the third (P<0.001 for

the comparison of the first and third groups and P = 0.01 for the comparison of

the first and second).

CONCLUSIONS: Treatment with peginterferon alfa-2a for 48 weeks, with or without

adefovir, resulted in sustained HDV RNA clearance in about one quarter of

patients with HDV infection.

(Current Controlled Trials number, ISRCTN83587695.).

PMID: 21268724 [PubMed - in process]